HALO logo
halo search icon
Lexicon Pharmaceuticals, Inc.

US$2.21

Price Change Indicator
0.08 (3.76%)
Lexicon Pharmaceuticals, Inc.
LXRX · NAS

Lexicon Pharmaceuticals, Inc.

Start Trading LXRX for Free

US$2.21

Price Arrow0.08 (3.76%)
20/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusHALO AllHALO Earnings MomentumHALO MomentumHALO Price Momentum
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Lexicon Pharmaceuticals, Inc. Overview

LXRX Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About LXRX

icon
icon

Telephone

1.281.863.3000

icon

Address

11th floor, 2445 Technology Forest Boulevard, The Woodlands, TX 77381-1160

Description

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

LXRX Price Chart

Key Stats

Market Cap

US$946.14M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.52 - 2.53

Trade Value (12mth)

US$920,730.00

1 week

-4.48%

1 month

16.39%

YTD

86.84%

1 year

247.13%

All time high

57.68

Key Fundamentals

EPS 3 yr Growth

-77.50%

EBITDA Margin

-97.00%

Operating Cashflow

-$68m

Free Cash Flow Return

-32.70%

ROIC

-24.30%

Interest Coverage

-5.80

Quick Ratio

4.90

Other Data

Shares Outstanding (Fully Diluted)

400m

HALO Sector

Healthcare

Next Company Report Date

11-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

LXRX Announcements

Latest Announcements

DateAnnouncements
08 May 26
08 May 26
08 May 26
07 May 26
07 May 26

LXRX Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
 $locklocklocklock-0.8-0.63-0.14locklocklock
EPS (Fully Diluted)
 $locklocklocklock-0.8-0.63-0.14locklocklock
Growth
 %locklocklocklock-30.221.877.9locklocklock
PE
 XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
 XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Lexicon Pharmaceuticals, Inc. (LXRX:NAS)?
Halo FAQ
The current share price of Lexicon Pharmaceuticals, Inc. (LXRX:NAS) is USD$2.21.
What is the 52-week high share price for Lexicon Pharmaceuticals, Inc. (LXRX:NAS)?
Halo FAQ
The 52-week high share price for Lexicon Pharmaceuticals, Inc. (LXRX:NAS) is USD$2.53.
What is the 52-week low share price for Lexicon Pharmaceuticals, Inc. (LXRX:NAS)?
Halo FAQ
The 52-week low share price for Lexicon Pharmaceuticals, Inc. (LXRX:NAS) is USD$0.52.
What is the dividend yield for Lexicon Pharmaceuticals, Inc. (LXRX:NAS)?
Halo FAQ
Lexicon Pharmaceuticals, Inc. (LXRX:NAS) does not pay a dividend.
What was Lexicon Pharmaceuticals, Inc. (LXRX:NAS) last dividend payment?
Halo FAQ
Lexicon Pharmaceuticals, Inc. (LXRX:NAS) does not pay a dividend.
What is the franking level for Lexicon Pharmaceuticals, Inc. (LXRX:NAS)?
Halo FAQ
Lexicon Pharmaceuticals, Inc. (LXRX:NAS) has a franking level of 0.00%.
In which sector is Lexicon Pharmaceuticals, Inc. (LXRX:NAS) classified?
Halo FAQ
Lexicon Pharmaceuticals, Inc. (LXRX:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial